You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Andrew Han covers breaking news for GenomeWeb. He tracks companies in the sequencing and diagnostic markets.
The firm's single-cell T cell receptor profiling method was published this month as part of a study to develop reusable antigen reactivity screens.
A nationwide, multi-agency effort to sequence the virus causing COVID-19 is a logistical nightmare, but experts say the UK is well situated to succeed.
The Delaware jury said Oxford Nanopore had infringed three patents, but also found that they were invalid, mostly because they were not enabled.
The Stanford University spinout claims it can get three times the nucleic acid yield as column- or magnetic bead-based methods, with less damage to the molecules.
Fulgent and its China-based joint venture are working on a clinical NGS-based test that it says will have better sensitivity than RT-PCR-based kits.
The method uses nanopore sequencing to analyze short cell-free DNA fragments from blood, providing results in as little as six hours.
The immune sequencing firm has engaged the FDA in discussions over how to get regulatory approval for one test for several seemingly different diseases.
The Cambridge, Massachusetts-based firm also said it tacked on $3 million to its Series B financing round for a total of $30 million.
The company plans to offer four new products by the end of the year, including four targeted transcriptomic panels and IHC compatibility for Visium.
Though 10x will phase out its linked reads technology, it plans to introduce targeted RNA-seq for Chromium and FFPE sample compatibility for Visium.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.